Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Eur J Nucl Med Mol Imaging

Search In Journal Title:

Abbravation: European Journal of Nuclear Medicine and Molecular Imaging

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

DOI

10.1007/s13224-014-0650-0

Search In DOI:

ISSN

1619-7089

Search In ISSN:
Search In Title Of Papers:

Coronary risk factors and myocardial blood flow in

Authors: Ibrahim Danad Pieter G Raijmakers Yolande E Appelman Hendrik J Harms Stefan de Haan Mijntje L P van den Oever Cornelis van Kuijk Cornelis P Allaart Otto S Hoekstra Adriaan A Lammertsma Mark Lubberink Albert C van Rossum Paul Knaapen
Publish Date: 2011/10/18
Volume: 39, Issue: 1, Pages: 102-112
PDF Link

Abstract

There has been increasing interest in quantitative myocardial blood flow MBF imaging over the last years and it is expected to become a routinely used technique in clinical practice Positron emission tomography PET using 15OH2O is the established gold standard for quantification of MBF in vivo A fundamental issue when performing quantitative MBF imaging is to define the limits of MBF in a clinically suitable population The aims of the present study were to determine the limits of MBF and to determine the relationship among coronary artery disease CAD risk factors gender and MBF in a predominantly symptomatic patient cohort without significant CADA total of 128 patients mean age 54 ± 10 years 50 men with a low to intermediate pretest likelihood of CAD were referred for noninvasive evaluation of CAD using a hybrid PET/computed tomography PET/CT scanner MBF was quantified with 15OH2O at rest and during adenosineinduced hyperaemia Obstructive CAD was excluded in these patients by means of invasive or CTbased coronary angiographyGlobal average baseline MBF values were 091 ± 034 and 109 ± 030  ml·min−1·g−1 range 054–235  and 059–275 ml·min−1·g−1 in men and women respectively p  001 However no genderdependent difference in baseline MBF was seen following correction for rate–pressure product 098 ± 045 and 109 ± 030 ml·min−1·g−1 in men and women respectively p = 008 Global average hyperaemic MBF values were 344 ± 120 ml·min−1·g−1 in the whole study population and 290 ± 085 and 378 ± 127 ml·min−1·g−1 range 152–522 and 172–815 ml·min−1·g−1 in men and women respectively p  0001 Multivariate analysis identified male gender age and body mass index as having an independently negative impact on hyperaemic MBFThere has been increasing interest in quantitative myocardial perfusion imaging over the last years and it is expected to become routinely implemented in clinical practice 1 2 3 Myocardial blood flow MBF measurements add incremental value to the diagnosis and evaluation of coronary artery disease CAD compared with qualitative perfusion imaging techniques 1 4 5 Furthermore quantitative MBF values can be used to evaluate the effect of lifestyle changes and pharmacological interventions in patients with CAD risk factors and impaired MBF Positron emission tomography PET is the established gold standard for quantitative MBF imaging 1 3 4 6 A number of PET tracers eg 13NNH3 82Rb and 15OH2O are currently available and are well validated 7 8 9 10 Nonetheless the number of studies that have routinely evaluated the use of quantitative MBF values in the diagnosis of CAD are scarce 5 11 One of the fundamental issues when performing quantitative MBF imaging is to define lower limits of hyperaemic MBF Although databases are available with normal MBF values these data were predominantly obtained in healthy volunteers in whom CAD had not been excluded 12 13 14 Furthermore the limits of MBF values obtained from these studies are of less clinical value taking into consideration that these studies were performed in asymptomatic individuals without multiple risk factors for CAD which are known to affect MBF even in the absence of epicardial atherosclerosis 15Therefore the aims of this study were to determine the limits of MBF and to investigate the impact of age gender and CAD risk factors on MBF using 15OH2O PET in a large clinical cohort of patients suspected of having and with risk factors for CAD but in whom significant CAD was excluded by invasive coronary angiography ICA or CTbased coronary angiography CTCA


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Protocol for measuring myocardial blood flow by PET/CT in cats
  2. Comparison of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate and [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotide: which peptide is preferable for PRRT?
  3. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography
  4. Assessment of the diagnostic accuracy of 18 F-FDG PET/CT in prosthetic infective endocarditis and cardiac implantable electronic device infection: comparison of different interpretation criteria
  5. Left ventricular diastolic dyssynchrony assessed with phase analysis of gated myocardial perfusion SPECT: a comparison with tissue Doppler imaging
  6. Non-invasive estimation of hepatic glucose uptake from [ 18 F]FDG PET images using tissue-derived input functions
  7. Non-invasive estimation of hepatic glucose uptake from [ 18 F]FDG PET images using tissue-derived input functions
  8. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
  9. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18 F-fluorocholine PET/CT
  10. Pharmacokinetics of [ 18 F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease
  11. Can 68 GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?
  12. Brain reserve capacity in frontotemporal dementia: a voxel-based 18 F-FDG PET study
  13. In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model
  14. Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [ 11 C]ABP688 PET
  15. Assessment of infarct size by positron emission tomography and [ 18 F]2-fluoro-2-deoxy- D -glucose: a new absolute threshold technique
  16. 99m TcO(BAT-NI), a novel nitroimidazole tracer: in vivo uptake studies in ischaemic myocardium
  17. How should we analyse FDG PET studies for monitoring tumour response?
  18. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction
  19. Positron emission tomography in the management of lymphomas: a summary
  20. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study
  21. Molecular imaging of angiogenesis with SPECT
  22. Impact of 131 I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma
  23. SPECT imaging of D 2 dopamine receptors and endogenous dopamine release in mice
  24. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p
  25. A comparison of 99m Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping
  26. α v β 3 imaging can accurately distinguish between mature teratoma and necrosis in 18 F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study
  27. Comparison of the pharmacokinetics of 68 Ga-DOTATOC and [ 18 F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90 Y-DOTATOC therapy
  28. Integrated SPECT/CT for assessment of haemodynamically significant coronary artery lesions in patients with acute coronary syndrome
  29. Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing
  30. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy
  31. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut
  32. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
  33. Functional sex differences in human primary auditory cortex
  34. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures
  35. Metabotropic glutamate receptor 5 – a promising target in drug development and neuroimaging
  36. Repeatability of hypoxia PET imaging using [ 18 F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial
  37. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia
  38. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer
  39. Erratum to: Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis
  40. Drug enhancement of myocardial tracer uptake during myocardial perfusion imaging
  41. Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG- 99m Tc-nanocolloid
  42. Occult lung infarction may induce false interpretation of 18 F-FDG PET in primary staging of pulmonary malignancies
  43. Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification
  44. Preoperative mapping of cortical language areas in adult brain tumour patients using PET and individual non-normalised SPM analyses
  45. Biodistribution and radiation dosimetry of 68 Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer
  46. From the atomon of Democritus to the therapeutic nuclear medicine of today
  47. Post-traumatic biliobronchial fistula demonstrated on hepatobiliary scintigraphy with SPECT/CT
  48. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer
  49. Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[ 18 F]-ADAM in rats and monkeys
  50. Development of 68 Ga-labelled DTPA galactosyl human serum albumin for liver function imaging
  51. Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?
  52. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer
  53. Validation of pixel-wise parametric mapping of myocardial blood flow with 13 NH 3 PET in patients with hypertrophic cardiomyopathy
  54. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery
  55. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
  56. Texture analysis of 18 F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy
  57. Texture analysis of 18 F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy
  58. PET imaging of HER1-expressing xenografts in mice with 86 Y-CHX-A″-DTPA-cetuximab
  59. Sensitivity of PET/MRI to detect recurrence of prostate cancer
  60. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results
  61. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer
  62. Metabolic-structural concordance in paraneoplastic limbic encephalitis
  63. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease
  64. Abnormal response to inotropic stimulation in young asymptomatic type I diabetic patients demonstrated by serial gated myocardial perfusion SPECT imaging
  65. The “reset button” revisited: why high activity 131 I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients
  66. Left ventricular dyssynchrony assessed by gated SPECT phase analysis is an independent predictor of death in patients with advanced coronary artery disease and reduced left ventricular function not undergoing cardiac resynchronization therapy
  67. FDG PET/CT methodology for evaluation of treatment response in lymphoma: from “graded visual analysis” and “semiquantitative SUVmax” to global disease burden assessment
  68. Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE
  69. EANM 2010—Welcome to Vienna!
  70. 18 F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer
  71. In vitro detection of mdr 1 mRNA in murine leukemia cells with 111 In-labeled oligonucleotide
  72. Therapeutic nuclear medicine expands to breast cancer
  73. Introduction to EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
  74. Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT 4 receptors with SPET
  75. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls
  76. Are Health Technology Assessments a reliable tool in the analysis of the clinical value of PET in oncology? Who audits the auditors?
  77. Defining optimal tracer activities in pediatric oncologic whole-body 18 F-FDG-PET/MRI
  78. The impact of reconstruction method on the quantification of DaTSCAN images
  79. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma
  80. Role of pre-operative imaging using 99m Tc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy
  81. Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?
  82. Radiation exposure to surgical staff during F-18-FDG-guided cancer surgery
  83. The role of 131 I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
  84. Breast lymphatic drainage via the pulmonary lymphatic system
  85. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source
  86. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype
  87. Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk
  88. Value of 11 C-choline PET and PET/CT in patients with suspected prostate cancer

Search Result: